Troglitazone (brand name Rezulin) is an anti-diabetic drug in the glitazones class.
Troglitazone was taken off the market in 2000 due to an increased incidence of drug-induced hepatitis in patients who were using the drug. It is now common practice that liver enzymes are monitored during the first year of treatment with the "newer" thiazolidinediones.
Wikipedia has an article related to: